You are here

Novel and Selective AMPK Activator for the Treatment of Hepatocellular Carcinoma

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA171389-01A1
Agency Tracking Number: R43CA171389
Amount: $225,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA13-088
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
First Flight Venture Center 2 Davis Drive
Research Triangle Park, NC 27709-0003
United States
DUNS: 962942863
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (919) 354-1066
Business Contact
Phone: (919) 406-4367
Research Institution

Project Summary/Abstract Liver cancer, primarily hepatocellular carcinoma (HCC), accounts for ~662,000 deaths each year and is the third leading cause of death from cancer worldwide. The age-adjusted incidence of HCC tripled between 1975 and 2005 in the US, and primary liver cancer mortality rates have increased faster than mortality for any other tumor type. One- and 3-year survival rates were 36% and 17%, respectively, in the Surveillance, Epidemiology and End Results (SEER) registries from 1998 to 2000.HCC is treated by aggressive surgery, liver transplantation, radiation, chemoembolization or chemotherapy. Only one drug (Nexavar/sorafenib) is approved for HCC and this extends life by a modest 4 months. The introduction of new and efficacious therapeuticoptions is critical for effective management of this disease, particularly in cases where tumor has spread to secondary sites. NovaTarg has established a novel approach to HCC treatment in which biguanides are designed to utilize transporters (OCT1 and O

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government